Molecular Testing for the MD Anderson Cancer Center Personalized Cancer Therapy Program

Recruiting

• Conditions: Glioma; Hematopoietic and Lymphoid Cell Neoplasm; Melanoma; Sarcoma; Malignant Solid Neoplasm

• Registration Number: NCT01772771
• Lead Sponsor: M.D. Anderson Cancer Center

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2013-1-14
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

Inclusion Criteria:<br><br> - Patients must have histologically, radiographic, or cytologically documented cancer,<br> suspected glioma, sarcoma, melanoma or hematologic cancer. Patients with benign<br> tumors may also be consented at the discretion of the attending physician if<br> molecular profiling is felt to have potential clinical implications.<br><br> - Patients must have the ability to understand and the willingness to sign a written<br> informed consent document<br><br> - Patients may be consented without confirming the amount and quality of archival<br> diagnostic or residual tissue available. However, research testing will only be<br> performed on patients who have sufficient archived diagnostic tissue or residual<br> tissue banked in one of the authorized tissue banks at MD Anderson available to<br> proceed with testing. The extent of testing may be modified based on amount of<br> tissue available. If any new tissue acquisition including a biopsy and/or surgical<br> resection etc. is being ordered for clinical care or another research study, or an<br> operation is being performed testing can be ordered on that sample<br><br> - Circulating cell-free deoxyribonucleic acid (cfDNA) Cohort: Circulating cell-free<br> DNA next generation sequencing (NGS) testing will be performed with the Clinical<br> Laboratory Improvement Act (CLIA)-certified Guardant360 panel (or equivalent) for<br> select patients. This particular cohort of research collaboration will be supported<br> by Guardant Health, Inc. at no charge to MD Anderson. Patients who are being<br> considered for enrollment into clinical trials in the next 2 lines of therapy may be<br> enrolled. Selected patients may have cfDNA, circulating RNA /exosome/circulating<br> tumor cell testing approaches performed on alternate platforms (eg Foundation ACT)

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Frequency of mutations and co-mutations;Distributions of mutations (including on gene expressions);Database of somatic mutations and clinical characteristics